Parenteral nitroglycerin: clinical usefulness and limitations.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Nitroglycerin is a traditional therapy for angina pectoris.
• Intravenous nitroglycerin has recently received FDA approval for clinical use.

Purpose of the Study:

• To explore the broader therapeutic applications of intravenous nitroglycerin.
• To compare the hemodynamic effects of intravenous nitroglycerin with sodium nitroprusside.

Main Methods:

• The study evaluated intravenous nitroglycerin's effects on left ventricular filling pressure, mean arterial pressure, and cardiac output.
• Hemodynamic responses were assessed in patients with ischemic heart disease, including those with severe left ventricular failure.
• Comparative analysis was performed against sodium nitroprusside regarding intercoronary collateral flow, pulmonary artery pressure, and intrapulmonary shunting.

Main Results:

• Intravenous nitroglycerin rapidly and predictably reduced left ventricular filling pressure and mean arterial pressure.
• Cardiac output augmentation was most pronounced in patients with severe left ventricular failure.
• Anti-ischemic effects were observed across all hemodynamic subgroups.
• Nitroglycerin demonstrated more favorable effects on collateral flow, pulmonary artery pressure, and intrapulmonary shunting compared to sodium nitroprusside.
• In the perioperative setting, nitroglycerin was as effective as nitroprusside for afterload reduction.

Conclusions:

• Intravenous nitroglycerin is a valuable tool for managing ischemic heart disease.
• Its favorable effects on coronary collateral resistance may make it preferable to sodium nitroprusside, especially in patients with obstructive coronary disease.